Atosiban SUN



This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Atosiban SUN. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Atosiban SUN.

For practical information about using Atosiban SUN, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 09/02/2022

Authorisation details

Product details
Atosiban SUN
Agency product number
Active substance
atosiban (as acetate)
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Premature Birth
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Sun Pharmaceutical Industries Europe B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Polarisavenue 87
2132JH Hoofddorp
The Netherlands

Product information

02/02/2022 Atosiban SUN - EMEA/H/C/002329 - IB/0021

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other gynecologicals

Therapeutic indication

Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:

  • regular uterine contractions of at least 30 seconds’ duration at a rate of ≥ 4 per 30 minutes;
  • a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%;
  • a gestational age from 24 until 33 completed weeks;
  • a normal foetal heart rate.

Assessment history

How useful was this page?

Add your rating
1 rating
1 rating